Please assess the completion status of the following clinical trial:

Trial Title: Macular Pigment and Visual Performance in Glaucoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* glaucoma diagnosis: To be considered glaucomatous, patients will be required to have: (1) history of elevated intraocular pressure (IOP; over 21 mmHg); (2) at least two consecutive and reliable standard automated perimetry (SAP) examinations with either a pattern standard deviation (PSD) outside the 95% normal limits or a glaucoma hemifield test (GHT) result outside the 99% normal limits; and/or glaucomatous optic neuropathy.~* between the ages of 18 and 75 years,~* must be able and willing to provide signed informed consent and follow study instructions.~Exclusion Criteria:~* no systemic disease, no other ocular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lutein, zeaxanthin and mesozeaxanthin (Type: ACTIVE_COMPARATOR): Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain 22 mg total of the carotenoids lutein (10 mg), zeaxanthin (2 mg), and mesozeaxanthin (10 mg).
- Placebo (Type: PLACEBO_COMPARATOR): Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain only sunflower oil (placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).